tiprankstipranks
Trending News
More News >

Immunic price target lowered to $5 from $6 at B. Riley

B. Riley analyst William Wood lowered the firm’s price target on Immunic (IMUX) to $5 from $6 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q1 report. Riley factored in the prospects of a likely near-term strategic financing to extend Immunic’s cash runway well beyond 2026.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1